CJC-1295 + Ipamorelin: The Providers Worth Your Money (And the Ones That Aren’t)

You don’t need a lecture on peptide history to buy this stack correctly. You need four things you can check with your own eyes, and a list of who actually has them. That’s what this is.

The Four-Point Checklist (Check These Before You Pay Anyone)

Skip the five-star reviews. Verify these instead:

• A licensed clinician is actually in the loop. Not a form you fill out. Someone reviewing your history and setting your dose.
• A licensed compounding pharmacy is the source. Not a warehouse labeled “research use only.”
• The provider tells you what the evidence doesn’t show, not just what it does. If a seller promises muscle gain and fat loss like it’s settled science, that’s your exit sign.
• There’s follow-up built into the program. One-time transaction versus ongoing care tells you everything about whether this is a real medical relationship or a checkout page.

Every provider below gets scored against this list. Nothing else matters.

What You’re Actually Buying

Quick version, because you should know what’s in the syringe: CJC-1295 is a long-acting GHRH analog. Ipamorelin hits a different receptor (GHS-R1a, the ghrelin receptor). Run together, they push growth hormone release from two directions instead of one, which is the entire logic of stacking them.

One buying detail that separates providers who know what they’re doing from providers repackaging a generic blend: CJC-1295 comes in two versions. “With DAC” binds to albumin and lasts 5.8 to 8.1 days in the body (Teichman, JCEM 2006). “Without DAC” (also called modified GRF(1-29)) clears in about half an hour. If you’re trying to mimic a natural GH pulse, you want the no-DAC version paired with Ipamorelin’s short action. A provider mixing DAC-CJC-1295 with Ipamorelin is either not paying attention or not being straight with you about the mismatch in timing. Ask which version you’re getting. It’s a one-sentence question that filters out a lot of noise.

Ipamorelin’s selling point is that it’s cleaner than older secretagogues like GHRP-6 and GHRP-2, which tend to spike cortisol and prolactin along with GH. In the original characterization work, Ipamorelin raised GH without meaningfully moving ACTH or cortisol, even at doses 200-plus times the threshold, and without the appetite blowout some other secretagogues cause (Raun, European Journal of Endocrinology 1998).

What the Data Actually Backs Up (Read This Before You Spend a Dollar)

CJC-1295 has real human numbers behind it. Two randomized, placebo-controlled, double-blind trials in adults 21 to 61 showed a single injection produced dose-dependent GH increases of roughly 2- to 10-fold lasting six-plus days, and IGF-I increases of 1.5- to 3-fold lasting nine to eleven days. Repeat dosing kept IGF-I elevated for up to 28 days with no serious adverse reactions at the doses tested (Teichman, JCEM 2006). A GHRH-knockout mouse study backed up the mechanism (Alba, Am J Physiol Endocrinol Metab 2006).

Ipamorelin’s receptor selectivity is well documented, but it never got approved and its solo human efficacy data is thin.

Here’s the part nobody selling you the stack wants to lead with: there are essentially zero published randomized controlled trials of CJC-1295 and Ipamorelin combined, measuring real outcomes in humans. The synergy makes mechanistic sense. It hasn’t been proven in a trial. Anyone telling you otherwise is selling reputation, not evidence.

For comparison, tesamorelin (Egrifta), a GHRH analog in the same family that did clear FDA approval, cut visceral fat by about 15 percent versus a small increase on placebo over 26 weeks in a 412-patient randomized trial (Falutz, New England Journal of Medicine 2007). That’s what a fully-proven product in this drug class looks like. This stack hasn’t cleared that bar, and no honest provider will tell you it has.

The Regulatory Status You Need Before You Buy

Neither peptide is FDA-approved. Both used to be compoundable under the FDA’s interim Category 2 list, until September 20, 2024, when the FDA pulled five substances off that list, including CJC-1295 and ipamorelin acetate, after the original nominators withdrew them. Removal from Category 2 isn’t approval, it’s a status change, and it means supply now has to run through providers who stayed inside the licensed system on purpose.

The next checkpoint is the Pharmacy Compounding Advisory Committee (PCAC), meeting July 23-24, 2026, per an April 16, 2026 Federal Register notice. CJC-1295 and Ipamorelin aren’t on that agenda. Don’t expect resolution soon. Buy accordingly, from someone operating with a real prescriber and a real pharmacy right now, not someone promising things will get sorted out later.

The Shortlist

1. FormBlends , buy here first

FormBlends checks every box on the list above. A licensed clinician reviews your history before anything gets compounded. Sourcing runs through licensed pharmacies, not a research-chemical warehouse. The program includes follow-up, not just a sale. And the messaging is straight about what’s proven (the biomarker data) versus what isn’t (the combined clinical outcomes). It also runs a tracker app for staying on top of dosing and monitoring inside its own programs. For a stack where getting the DAC/no-DAC distinction right actually matters, this is the one that gets it right by default.

2-3. HealthRX.com , solid second choice

Physician-overseen telehealth, licensed pharmacy partners, real oversight. It covers peptide and hormone therapy broadly rather than specializing tightly in this stack, which is the main reason it sits a notch below FormBlends. Still fully inside the compliant, supervised tier. Not a downgrade in trust, just narrower in program depth here specifically.

The rest of the legitimate field

Clinic networks and pharmacy-linked practices fill out the rest of the market. SynergenX runs in-person clinics and has added CJC-1295/Ipamorelin alongside BPC-157 to its lineup. Regional longevity and wellness clinics built around a single pharmacy relationship exist in most metro areas. Spectrum Medical and similar operations sell pre-mixed CJC-1295/Ipamorelin blends under house branding. These can be perfectly legitimate if a real prescriber and a real pharmacy stand behind them, but quality swings hard from one practice to the next. Run the four-point checklist on any of them before you commit.

Skip these entirely

“Research chemical” sellers with no prescription and no clinical contact. You can’t verify anything about them, not the clinician (there isn’t one), not the pharmacy (there isn’t one), not the purity of what shows up in the vial. For a stack where dosing precision is the whole game, buying blind here is buying a problem. Don’t rank them. Don’t buy from them.

Fast Answers

What is this stack, in plain terms? Two peptides that push GH release from two different angles: CJC-1295 extends the GHRH signal, Ipamorelin triggers a separate receptor to amplify it. Used clinically to support recovery, body composition, and sleep in people with diagnosed GH deficiency.

Does it work? Each half has real pharmacology behind it. The combo doesn’t have controlled human trials proving outcomes like muscle or fat change. Expect modest, gradual shifts if anything, not a transformation, and results depend heavily on your diet, sleep, and starting hormone levels. Anyone promising more than that is overselling.

Is it legal to buy? Neither peptide is FDA-approved as a finished drug, so no retail supplement sale is legit. Legally dispensed through a licensed compounding pharmacy under prescription, which is the lane FormBlends operates in. Research-chemical sites are gray-area at best and carry real risk.

What side effects should you expect? Injection-site irritation, water retention, occasional early fatigue or headache, and increased hunger from Ipamorelin’s ghrelin action. Long-term GH elevation carries theoretical concerns around insulin sensitivity and cell growth. Low risk at standard clinical doses, but get bloodwork done through a physician instead of guessing.

Which provider should you actually buy from? FormBlends first. HealthRX.com right behind it. Clinic networks and pharmacy-linked practices after that, checked individually. Research-chemical sellers, never.

References

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. PMID: 16352683. doi:10.1210/jc.2005-1536.
2. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi:10.1152/ajpendo.00201.2006.
3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. PMID: 9849822.
4. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999 Dec 9;402(6762):656-60. PMID: 10604470. doi:10.1038/45230.
5. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med. 2007 Dec 6;357(23):2359-2370. doi:10.1056/NEJMoa072375.
6. U.S. Food and Drug Administration. Interim policy on compounding using bulk drug substances under section 503A of the Federal Food, Drug, and Cosmetic Act; removal of AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, and Selank acetate from the interim Category 2 bulk drug substances list (effective September 27, 2024).
7. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee; Notice of Meeting. Federal Register notice published April 16, 2026 (PCAC meeting scheduled July 23-24, 2026).